Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27445D
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company focuses on thrombosis, anesthetics and high potency and cytotoxics therapeutic categories. It also manufactures infant nutritionals and consumer healthcare products in selected territories. Its manufacturing capabilities cover a range of product-types including oral solid dose, semi-solids, liquids, steriles, biological, active pharmaceutical ingredients (APIs) and infant nutritionals. The company has presence in Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Ltd (APN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16

Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17

Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18

Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19

Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20

Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21

Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22

Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23

Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25

Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27

Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For USD 257 Million 28

Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For USD 263 Million 31

Partnerships 33

Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33

AstraZeneca Enters into Co-Marketing Agreement with Aspen 34

ANI Pharma Enters into Distribution Agreement with Aspen 35

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36

Navamedic Amends Distribution Agreement With Aspen Pharma 37

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38

Licensing Agreements 39

Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39

Aspen Pharma Enters into Licensing Agreement with Starpharma 40

Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41

TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42

QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43

QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44

Equity Offering 45

Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45

Asset Transactions 47

Endo International Acquires Portfolio of Branded and Generic Products 47

Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48

Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49

Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 52

Acquisition 53

GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53

GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For USD 696.5 Million 54

Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For USD 18.6 Million 55

Aspen Pharmacare Holdings Ltd-Key Competitors 56

Aspen Pharmacare Holdings Ltd-Key Employees 57

Aspen Pharmacare Holdings Ltd-Locations And Subsidiaries 58

Head Office 58

Other Locations & Subsidiaries 58

Joint Venture 61

Recent Developments 62

Financial Announcements 62

Mar 08, 2018: Aspen delivers double digit revenue and earnings growth 62

Sep 14, 2017: Aspen increases revenue by 16% to R41.2 billion 65

Mar 09, 2017: Aspen: Unaudited interim financial results for the six months ended 31 December 2016 68

Legal and Regulatory 71

Jun 13, 2017: Aspen: South African Competition Commission Announcement 71

May 15, 2017: Aspen: Opening of European Commission proceedings 72

Apr 24, 2017: Aspen's response to the reported Competition Commission investigation 73

Government and Public Interest 74

May 29, 2017: Aspen Cleared of Alleged Anti-competitive Behavior by DA 74

May 15, 2017: Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines 75

Other Significant Developments 77

Oct 26, 2018: Aspen's participation in the 2018 Investment Conference 77

Mar 01, 2017: Aspen-Trading Statement 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79

List of Figures

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12

List of Tables

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Aspen Pharmacare Holdings Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Aspen Pharmacare Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16

Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17

Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18

Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19

Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20

Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21

Aspen Pharmacare Acquires Rights to Mono-Embolex from Novartis 22

Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23

Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 25

Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 27

Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For USD 257 Million 28

Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For USD 263 Million 31

Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 33

AstraZeneca Enters into Co-Marketing Agreement with Aspen 34

ANI Pharma Enters into Distribution Agreement with Aspen 35

Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 36

Navamedic Amends Distribution Agreement With Aspen Pharma 37

Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 38

Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 39

Aspen Pharma Enters into Licensing Agreement with Starpharma 40

Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 41

TesoRx Pharma Enters into Licensing Agreement with Aspen Global 42

QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 43

QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 44

Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 45

Endo International Acquires Portfolio of Branded and Generic Products 47

Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 48

Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 49

Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 50

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 51

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 52

GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 53

GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For USD 696.5 Million 54

Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For USD 18.6 Million 55

Aspen Pharmacare Holdings Ltd, Key Competitors 56

Aspen Pharmacare Holdings Ltd, Key Employees 57

Aspen Pharmacare Holdings Ltd, Other Locations 58

Aspen Pharmacare Holdings Ltd, Subsidiaries 58

Aspen Pharmacare Holdings Ltd, Joint Venture 61

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aspen Pharmacare Holdings Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com